CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Amphastar Pharmaceuticals
AMPH
$1.37B
| $58K | 0.02% |
1,261
+628
| +99% | +$28.9K |
|
227
Xenon Pharmaceuticals
XENE
$3.02B
| $56.4K | 0.02% |
1,651
+818
| +98% | +$27.9K |
|
228
Beam Therapeutics
BEAM
$2.11B
| $54.6K | 0.02% |
2,272
+1,037
| +84% | +$24.9K |
|
229
Ambarella
AMBA
$3.54B
| $53K | 0.02% |
1,000
| – | – |
|
230
Ventyx Biosciences
VTYX
$180M
| $52.3K | 0.02% |
1,506
+739
| +96% | +$25.7K |
|
231
JD.com
JD
$44.6B
| $51.1K | 0.01% |
1,754
+1,042
| +146% | +$30.4K |
|
232
Harmony Biosciences
HRMY
$2.07B
| $50.2K | 0.01% |
1,533
+748
| +95% | +$24.5K |
|
233
Lucid Motors
LCID
$5.66B
| $47.3K | 0.01% |
847
+640
| +309% | +$35.8K |
|
234
Arcellx
ACLX
$4.03B
| $44.8K | 0.01% |
1,248
+619
| +98% | +$22.2K |
|
235
NovoCure
NVCR
$1.37B
| $44.2K | 0.01% |
2,739
+1,347
| +97% | +$21.8K |
|
236
PTC Therapeutics
PTCT
$4.55B
| $43.5K | 0.01% |
1,941
+969
| +100% | +$21.7K |
|
237
Immunocore
IMCR
$1.87B
| $43.4K | 0.01% |
836
+426
| +104% | +$22.1K |
|
238
STAAR Surgical
STAA
$1.38B
| $42.9K | 0.01% |
1,067
-43,138
| -98% | -$1.73M |
|
239
Rocket Pharmaceuticals
RCKT
$354M
| $42.4K | 0.01% |
2,068
+1,014
| +96% | +$20.8K |
|
240
Crinetics Pharmaceuticals
CRNX
$3.35B
| $41.7K | 0.01% |
1,403
+695
| +98% | +$20.7K |
|
241
Veracyte
VCYT
$2.55B
| $41.6K | 0.01% |
1,862
+913
| +96% | +$20.4K |
|
242
Recursion Pharmaceuticals
RXRX
$2.01B
| $40.1K | 0.01% |
5,237
+2,817
| +116% | +$21.6K |
|
243
IDEAYA Biosciences
IDYA
$2.38B
| $39.8K | 0.01% |
1,474
+723
| +96% | +$19.5K |
|
244
CureVac
CVAC
$1.21B
| $39.2K | 0.01% |
5,738
+2,804
| +96% | +$19.2K |
|
245
Supernus Pharmaceuticals
SUPN
$2.58B
| $38.6K | 0.01% |
1,401
+687
| +96% | +$18.9K |
|
246
Ironwood Pharmaceuticals
IRWD
$188M
| $38.5K | 0.01% |
3,997
+1,961
| +96% | +$18.9K |
|
247
Genmab
GMAB
$16.9B
| $37.9K | 0.01% |
1,075
+498
| +86% | +$17.6K |
|
|
CBAY
248
DELISTED
Cymabay Therapeutics
CBAY
| $37.5K | 0.01% |
2,516
+1,238
| +97% | +$18.5K |
|
|
SWTX
249
DELISTED
SpringWorks Therapeutics
SWTX
| $37.3K | 0.01% |
1,612
+792
| +97% | +$18.3K |
|
250
Pacira BioSciences
PCRX
$1.19B
| $36.4K | 0.01% |
1,185
+583
| +97% | +$17.9K |
|